IRIS
FUMAROLA, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.071
EU - Europa 3.078
AS - Asia 2.950
SA - Sud America 479
AF - Africa 163
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.748
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.004
SG - Singapore 1.233
CN - Cina 995
IT - Italia 841
IE - Irlanda 431
FI - Finlandia 410
BR - Brasile 392
SE - Svezia 389
DE - Germania 285
HK - Hong Kong 217
VN - Vietnam 156
UA - Ucraina 133
NL - Olanda 110
GB - Regno Unito 100
ZA - Sudafrica 93
IN - India 86
TR - Turchia 80
RU - Federazione Russa 78
FR - Francia 76
AT - Austria 54
BE - Belgio 49
CA - Canada 44
CI - Costa d'Avorio 40
AR - Argentina 36
PL - Polonia 30
ES - Italia 23
ID - Indonesia 23
BD - Bangladesh 22
KR - Corea 22
CZ - Repubblica Ceca 20
JP - Giappone 17
EC - Ecuador 16
IQ - Iraq 15
MX - Messico 14
PK - Pakistan 13
CO - Colombia 12
PS - Palestinian Territory 10
IR - Iran 9
LT - Lituania 9
MA - Marocco 8
VE - Venezuela 8
UZ - Uzbekistan 7
LU - Lussemburgo 6
EG - Egitto 5
HU - Ungheria 5
KG - Kirghizistan 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
JO - Giordania 4
KE - Kenya 4
LB - Libano 4
NP - Nepal 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
TN - Tunisia 4
AZ - Azerbaigian 3
CH - Svizzera 3
MD - Moldavia 3
PE - Perù 3
QA - Qatar 3
RO - Romania 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AO - Angola 2
BO - Bolivia 2
CL - Cile 2
CY - Cipro 2
EE - Estonia 2
JM - Giamaica 2
KZ - Kazakistan 2
MY - Malesia 2
NO - Norvegia 2
PA - Panama 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
NI - Nicaragua 1
OM - Oman 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
Totale 10.744
Salva come PNG Salva come JPEG
Città #
Singapore 679
Dallas 627
Dublin 431
Ashburn 409
Chandler 392
Ann Arbor 338
Santa Clara 273
Parma 272
Beijing 223
Hong Kong 215
Dearborn 155
Jacksonville 144
Boardman 131
New York 115
Shanghai 98
Los Angeles 94
Munich 92
Hefei 88
Johannesburg 88
Nanjing 84
Milan 70
Princeton 67
Izmir 65
Bremen 60
Helsinki 49
Ho Chi Minh City 47
Vienna 46
Nanchang 41
Abidjan 40
Chicago 40
San Mateo 40
São Paulo 39
Shenyang 37
Moscow 34
Wilmington 34
Brussels 31
Buffalo 31
Modena 30
Hanoi 29
Kunming 28
Bologna 27
Columbus 27
Hebei 27
Jinan 24
The Dalles 24
Tianjin 24
Marseille 23
Seattle 23
Warsaw 23
Des Moines 22
Seoul 21
Jakarta 20
London 20
Redmond 20
Turku 20
Council Bluffs 18
Toronto 18
Nuremberg 17
Woodbridge 17
Denver 16
Frankfurt am Main 15
Pune 15
Stockholm 15
Tokyo 15
Amsterdam 14
Manchester 14
Norwalk 14
Phoenix 14
Reggio Emilia 14
Bari 13
Changsha 13
Chennai 13
Guangzhou 13
Poplar 13
Rio de Janeiro 13
Brescia 12
Jiaxing 12
Neviano degli Arduini 12
Rome 12
Wayne 12
Leawood 11
Montreal 11
Boston 10
Florence 10
Fremont 10
Houston 10
Zhengzhou 10
Brasília 9
Gaza 9
Haiphong 9
Augusta 8
Bengaluru 8
Brooklyn 8
Dong Ket 8
Fuzhou 8
Grafing 8
New Delhi 8
Orem 8
San Jose 8
Verona 8
Totale 6.684
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 313
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 222
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 207
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 206
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 204
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 186
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 181
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 179
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 172
Novel activity of a synthetic decapeptide against Toxoplasma gondii Tachyzoites 171
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 170
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 165
Characterization of gefitinib uptake in NSCLC cell lines 164
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 164
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 164
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 162
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 158
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 157
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 156
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 153
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 152
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 150
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 149
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 149
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 149
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 149
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 148
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 148
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 147
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 147
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 146
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 146
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 141
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 141
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 139
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 138
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 136
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 135
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 135
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 134
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 132
Physico-chemical characterization and biological evaluation of two fibroin materials 131
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 129
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 129
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 129
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 126
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 121
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 118
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 116
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 116
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 115
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 114
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 113
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 111
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 110
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 110
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 108
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 105
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 103
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 101
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 101
Immunotherapeutic approaches in malignant pleural mesothelioma 98
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways 94
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 92
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 92
Effect of inducible FHIT and p53 expression on CALU-1 cell proliferation. 90
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 88
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 87
Synergistic activity of letrozole and sorafenib on breast cancer cells 86
Increased level of inducible HSP70 in cells exposed to electromagnetic fields. 86
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 86
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 84
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 83
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer 83
Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" 83
Targeting FGFR1 pathway in squamous cell lung cancer 83
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 83
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 77
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 74
New therapeutic strategies for malignant pleural mesothelioma 73
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 70
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 67
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 58
Effect of constitutive expression of the fragile histidine triad gene on non small cell lung cancer 48
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) 42
null 31
Effects of sorafenib on energy metabolism in breast cancer cells: Role of AMPK-mTORC1 signaling 14
Totale 10.923
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.232
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.232
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021356 0 0 0 0 0 16 48 30 86 23 113 40
2021/2022418 36 15 21 38 15 10 70 30 21 19 30 113
2022/20231.685 147 178 118 107 158 192 14 141 527 9 73 21
2023/2024800 38 49 28 43 54 156 67 68 33 45 89 130
2024/20252.438 87 110 167 178 249 259 177 124 283 199 205 400
2025/20263.174 427 480 797 537 721 212 0 0 0 0 0 0
Totale 10.923